Whitespace Analysis

Find crowded markets, emerging opportunities, and underserved indications by trial activity and sponsor concentration.

Limited-time launch pricing

$99/month

30-day free trial - no credit card

Upgrade to Pro

Or explore free dashboards — PDUFA calendar, Trials Explorer, Biotechs, and more.

Competitive Density Analysis

Data updated: Jun 28, 2026

Trial activity, Phase 3 concentration, and competitive dynamics by indication

Current Metrics: Based on ClinicalTrials.gov data (active trials, phases, sponsors).

Future Enhancement: True "white space" analysis (trials vs approved drugs) requires mapping FDA-approved drugs to our indication taxonomy. FDA labels use specific terms like "HER2+ metastatic breast carcinoma" while our taxonomy uses broader categories like "Breast Cancer". This mapping is in progress.

Highest Trial Activity

Most active indications by total trial count

Indication	TA	Active Trials	Phase 3	Phase 2	Sponsors
Solid Tumor (Advanced)	Oncology	3521	380	1773	777
Non-Hodgkin Lymphoma	Oncology	1626	180	1026	232
Breast Cancer	Oncology	1516	327	885	195
NSCLC	Oncology	1467	284	878	325
Colorectal Cancer	Oncology	1146	188	720	232
Prostate Cancer	Oncology	879	162	522	150
AML	Oncology	703	79	371	114
Multiple Myeloma	Oncology	678	113	389	91
Pancreatic Cancer	Oncology	654	73	400	193
Hepatocellular Carcinoma	Oncology	626	93	374	121
Lung Cancer (General)	Oncology	564	77	341	105
Hematologic Malignancies	Oncology	550	60	316	81
Ovarian Cancer	Oncology	550	83	297	163
Head and Neck Cancer	Oncology	533	56	335	154
Melanoma	Oncology	521	60	306	143

Late-Stage Concentration

Highest Phase 3 activity (near-term competitive pressure)

Indication	TA	Phase 3	% of Trials	Active	Sponsors
Solid Tumor (Advanced)	Oncology	380	11%	3521	777
Breast Cancer	Oncology	327	22%	1516	195
NSCLC	Oncology	284	19%	1467	325
Colorectal Cancer	Oncology	188	16%	1146	232
Non-Hodgkin Lymphoma	Oncology	180	11%	1626	232
Prostate Cancer	Oncology	162	18%	879	150
Stroke	Cardiovascular	159	43%	374	54
Obesity	Metabolic	139	27%	518	91
Multiple Myeloma	Oncology	113	17%	678	91
Acute Pain	Pain	98	25%	397	43
Hypertension	Cardiovascular	97	29%	331	91
Hepatocellular Carcinoma	Oncology	93	15%	626	121

Concentrated Markets

Few sponsors running many trials (potential dominance or acquisition targets)

Indication	TA	Trials/Sponsor	Active	Sponsors
H. pylori	Infectious Disease	18.7	56	3
HIV	Infectious Disease	18.3	311	17
Chronic Pain	Pain	15.8	63	4
Postoperative Pain	Pain	15.2	182	12
Opioid Use Disorder	CNS	14.3	129	9
Sepsis	Infectious Disease	14.1	113	8
ADHD	CNS	13	39	3
Atrial Fibrillation	Cardiovascular	12.5	125	10
Alcohol Use Disorder	CNS	12.3	111	9
Nausea/Vomiting	Gastrointestinal	11.5	46	4

Fragmented Markets

Many sponsors competing (crowded, potentially commoditized)

Indication	TA	Sponsors	Active	Phase 3
Solid Tumor (Advanced)	Oncology	777	3521	380
NSCLC	Oncology	325	1467	284
Non-Hodgkin Lymphoma	Oncology	232	1626	180
Colorectal Cancer	Oncology	232	1146	188
Breast Cancer	Oncology	195	1516	327
Pancreatic Cancer	Oncology	193	654	73
Ovarian Cancer	Oncology	163	550	83
Head and Neck Cancer	Oncology	154	533	56
Prostate Cancer	Oncology	150	879	162
Melanoma	Oncology	143	521	60

Showing top indications in each category

Upgrade to Pro for full competitive density analysis across 150 indications

See Pro Features

Methodology

Data Source: ClinicalTrials.gov (Phase 2-4 interventional drug trials, 2008+)

Active Trials: Status = Recruiting, Active, or Enrolling by Invitation

Trials/Sponsor: Average trials per company in that indication. Higher = concentrated market.

Phase 3 %: Proportion of active trials in Phase 3. Higher = more near-term competitive pressure.